SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.60, for a total value of $38,000.00. Following the sale, the chief technology officer owned 182,171 shares of the company’s stock, valued at approximately $1,384,499.60. This represents a 2.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $7.67 on Tuesday. The firm has a 50 day moving average of $5.68 and a 200 day moving average of $5.16. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $643.44 million, a price-to-earnings ratio of -6.67 and a beta of 0.96. SOPHiA GENETICS SA has a 12-month low of $2.96 and a 12-month high of $7.88.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC boosted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $2,157,000. Royce & Associates LP purchased a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $2,009,000. Finally, Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the first quarter valued at $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research boosted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, HC Wainwright raised their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.